Mark S. Albom

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Bruce Ruggeri, J. B. Singh, Diane E. Gingrich et al. · PubMed · 2003 · 124 citations

Chemoprevention Strategy, Antitumor Efficacy, Tumor Biology +19

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

Weihua Wan, Mark S. Albom, Lihui Lü et al. · Blood · 2005 · 105 citations

Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis

Rabindranath Tripathy, Alyssa Reiboldt, Patricia A. Messina et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 104 citations · Full text

Medicinal Chemistry, Drug Target, Medicine +9

1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors

Rabindranath Tripathy, Arup K. Ghose, J. B. Singh et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 89 citations · Full text

Medicinal Chemistry, Medicine, Rational Drug Design +5

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 88 citations · Full text

Tumor Biology, Clinical Candidate Cep-37440, Lymphoid Neoplasia +14